C4 Therapeutics

Monofunctional Degradation Activating Compounds: From New Targets to the Clinic

TPD Summit, October 2022

Chris Nasveschuk on behalf of the C4 Team

Forward-looking Statements and Intellectual Property

Forward-looking Statements

The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. These forward-looking statements include, but are not limited to, statements regarding the therapeutic potential of C4 Therapeutics, Inc.'s technology and products. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, as well as the fact that the product candidates that we are developing or may develop may not demonstrate success in clinical trials. Prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. C4 Therapeutics, Inc. undertakes no obligation to update or revise the information contained in this presentation, whether as a result of new information, future events or circumstances or otherwise.

Intellectual Property

C4 Therapeutics, Inc. owns various registered and unregistered trademarks and service marks in the U.S. and internationally, including, without limitation, C4 THERAPEUTICS, our housemark logo, the name of our TORPEDO platform, and the names of our BIDAC and MONODAC degrader products. All trademarks, service marks, or trade names referred to in this presentation that we do not own are the property of their respective owners. Solely for convenience, the trademarks, service marks, and trade names in this presentation are referred to without the symbols ®, SM, and ™, but those references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.

Targeted Protein Degradation Has the Potential to Transform Treatment of Disease



TPD Has an Expansive Target Landscape

85% of proteins are currently undruggable or poorly drugged

TPD Offers a Powerful Modality

Benefits of genetic knockdown with a small molecule approach

C4T's TORPEDO platform creates therapeutic candidates that have the potential to improve patient care

- Overcome Resistance
- Drug Undruggable Targets
- Improve Treatment Options

Source: Hopkins, A., Groom, C. The druggable genome. Nat Rev Drug Discov 1, 727–730 (2002).

The Human Body Has A Natural Process to Destroy Unwanted Proteins



Targeted Protein Degradation Leverages the Body's Natural Process to Destroy Disease-Causing Proteins



TORPEDO Platform Offers Flexibility to Design MonoDAC and BiDAC Degraders

MonoDAC Degrader



BiDAC Degrader



Flexibility to Address Different Targets with Tailored Approach

Molecular Glue Degraders (MGDs) in the Literature



Thalidomide-related Zinc Finger degraders



Science **2018**, *362(6414)*, eaat0572



Lenalidomide, CK1-α degrader



Nature **2016**, *532(7597)*, 127



CC-885/90009 GSPT1 degraders



Nature **2016**, *535(7611)*, 252

MGDs Literature in the Literature





β-turn is the primary recognition element, secondary interactions play a role in activity and selectivity

Science **2018**, *362(6414)*, eaat0572

Why MonoDAC Degraders and Molecular Glue Degraders?

Disease Target and Potential for New Medicines

- Access to Not-Yet-Drugged/or Unligandable Targets
- MonoDAC degraders and MGDs exhibit degradation-only pharmacology

Drug Properties and Performance

- Access to degrader drug candidates within more traditional Rule of 5 physicochemical property space

MonoDAC Degraders and MGDs should be aligned to the right target and clinical opportunities

C4 Therapeutics

Identification and Characterization of MonoDAC CFT7455

C4T MonoDAC Library: Expanding the Cereblon Toolbox

Commercially available MonoDACs
C4T MonoDAC library

Commercially available MonoDACs cover a small subset of property space

C4T monoDAC library covers significantly larger portion



Drug-like property space



>5,000 membered library constructed from >200 unique scaffolds to maximize MonoDAC structural diversity and CRBN surface remodeling

C4 Therapeutics

C4T MonoDAC Library in Action



C4T MonoDAC Library has produced hits to novel MonoDAC Targets and a development candidate

C4 Therapeutics

Deep Structural Design Expertise of MonoDAC Degraders

Benzoimidazolone

C4T unpublished

1.17 Å



Compound 1

CRBN FP K_D = 830 nM

IKZF1▼

Pomalidomide

PDB 6h0f



Pomalidomide

K_D = 1600 nM

IKZF1▼

Deep Structural Design Expertise of MonoDAC Degraders

Benzoimidazolone

C4T unpublished

1.17 Å



Compound 1

CRBN FP K_D = 830 nM

IKZF1▼

Pomalidomide

PDB 6h0f



Overlay with Compound 1

Pomalidomide

K_D = 1600 nM

IKZF1▼

CRBN, cereblon; FP, fluorescence polarization; IKZF1, Ikaros family zinc finger protein 1.

C4 Therapeutics

Deep Structural Design Expertise of MonoDAC Degraders

Benzoimidazolone
C4T unpublished
1.17 Å



Compound 1
CRBN FP K_D = 830 nM
IKZF1▼

Pomalidomide
PDB 6h0f



Overlay with Compound 1

Pomalidomide
K_D = 1600 nM
IKZF1▼

50-fold affinity increase

Benzoisoindolinone
C4T unpublished
1.06 Å



Compound 2
K_D = 34 nM
IKZF1▼

CRBN, cereblon; FP, fluorescence polarization; IKZF1, Ikaros family zinc finger protein 1.

Exploring CRBN Interactions with the Potent Tricyclic Core

Tri-Trp Pocket Interactions



Increased Hydrophobic Contacts with CRBN



+δ Aromatic C-H Interactions with Backbone Carbonyl



C4 Therapeutics

CFT7455, A Highly Potent and Selective MonoDAC Degrader

CFT7455





IKZF1/3 Degradation, H929 (4 hr)



H929 cells, 4 hr

GPE in RPMI-8226, 10 nM (4 hr)



GPE, global proteomics experiment; IKZF1/3, Ikaros family zinc finger proteins 1 and 3.
C4 Therapeutics data on file.

CFT7455, A Highly Potent and Selective MonoDAC Degrader

Linear, Durable Tumor PK



48 hr Degradation Kinetics



IKZF3 PD Associated with Efficacy



CFT7455 displays linear and durable tumor PK translating into deep IKZF3 degradation and regression in MM xenograft models

IKZF3, Ikaros family zinc finger protein 3; MM, multiple myeloma; PD, pharmacodynamics; PK, pharmacokinetics, QD; once daily.
C4 Therapeutics data on file.

C4 Therapeutics

Finding MonoDAC Hits to Novel Neosubstrates

Strategic Approach to MonoDAC Hit Identification

In Silico Ternary Complex Design

- Identify G-loop containing proteins across the proteome
- Generate ternary complex models that inspire new monoDAC design
- *Approach does not necessarily identify productive degraders*

Ternary Complex Identification

- Develop high-throughput biochemical methods to identify ternary complex formation
- Develop high-throughput cellular assay methods to identify ternary complex formation
- *Approaches do not necessarily identify productive degraders*

Cellular Degradation

- HiBiT assay – mechanism-informed reduction of target protein levels
- *Off-target/off-mechanism and off-target/on-mechanism activity could confound hit identification*

A comprehensive approach that will also identify and expand MonoDAC degrons

C4T MonoDAC Library in Action – Cellular Degradation of Specific Target

Commercially available MonoDACs
C4T MonoDAC library

Commercially available MonoDACs cover a small subset of property space

C4T monoDAC library covers significantly larger portion



Drug-like property space



C4T MonoDAC Library has produced hits to novel MonoDAC Targets and a development candidate

C4 Therapeutics

C4T MonoDAC Library in Action – Cellular Degradation of Target A

HiBiT Cellular Degradation

Dose-Response Hit Identification



Endogenous Degradation

Western Blot



- 6hr Timepoint
- 73% Remaining

Identified hit reduces tagged and endogenous Target A protein levels

C4T MonoDAC Library in Action – Biochemical Ternary Complex

- AlphaLISA assay format
- Ternary complex between Target A and CRBN
- Analysis of library subset shown



Biochemical screen of the MonoDAC library identifies the same hit compound

C4T MonoDAC Library – Hit Validation

CRBN Engagement
Biochemical FP Assay



Mechanism of Action Confirmation



Canonical G-loop Anti-Targets



No degradation of IKZF1 and SALL4

Compound 3 demonstrates selective on-target, on-mechanism degradation of Target A

MonoDAC and BiDAC: Target-Tailored Approach

MonoDAC



BiDAC



C4T's Platform has produced both MonoDAC and BiDAC Development Candidates

C4 Therapeutics

Thank You C4T Team